secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-105039
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q2 revenue $47.4M (+7% YoY); net loss narrows to $17.4M; FY guidance reaffirmed
--------------------------------------------------------------------------------

- Revenue $47.4M in Q2 2025, up 7% from $44.5M in Q2 2024.
- Net loss $(17.4)M ($(0.28)/share) vs $(21.2)M ($(0.34)/share) a year ago; 18% improvement.
- Adjusted EBITDA loss improved 58% to $(3.6)M from $(8.7)M in Q2 2024.
- Total liquidity $90.7M as of June 30, 2025 ($69.3M cash plus $21.4M revolver).
- Full market release of Nanoplasty, Percuplasty 3D MIS Osteotomy, and SpeedMTP Fusion Systems.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017025105039/0000950170-25-105039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017025105039/tmci-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-105039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer